SCIB Share Price Performance
SEK 0.34
-0.16 (-31.88%)
Price SEK 0.34
Share PriceSEK 0.34
Estimating The Intrinsic Value Of SciBase Holding AB (publ) (STO:SCIB)
Apr 04
SciBase Holding AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
SCIB Community Narratives
There are no narratives available yet.
SciBase Holding AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 07, 2025
- Earnings per share (EPS)
- -0.22
- Gross Margin
- 70.17%
- Net Profit Margin
- -257.73%
- Debt/Equity Ratio
- 0%
SciBase Holding AB (publ) Competitors
Snowflake Analysis
About SCIB
- Founded
- 1998
- Employees
- 34
- CEO
- WebsiteView website
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment. It has a collaboration with Mayo Clinic on pigmented lesion digital workflows with AI-driven Nevisense; Vrije Universiteit Brussel University hospitals for a study geared toward predicting atopic dermatitis and concomitant atopic diseases, such as asthma and hay fever in infants. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swedish Market Performance
- 7 Days: 1.7%
- 3 Months: 2.4%
- 1 Year: -0.5%
- Year to Date: 2.9%
The market has climbed 1.7% in the last 7 days, lead by the Industrials sector with a gain of 2.6%. The market has been flat overall in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›